Institution:
A new family of molecules against a novel therapeutic target which is overexpressed in HNSCC and related with the resistance acquisition developed by HNSCC patients after chemotherapy.
TspanCure
Tackling cancer heterogeneity: a breakthrough in overcoming chemoresistant tumors First-in-class drugs against a new therapeutic target whose overexpression is involved in the malignancy of very specific cancer types, including HNSCC, pancreatic, breast, among others.
Research Group:
Biomedical Research in Cancer Stem Cells
Researcher/s:
Dr. Matilde E. LLeonart, Dr. Gerard Pujadas, Dr. Amadeu Llebaria
Description:
Problem:
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and the overall 5-year survival rate remains approximately 40% to 50%. More than 50% of HNSCC patients develop therapy resistance after conventional treatments such as chemotherapy. Currently, there is a lack of treatment for resistant HNSCC tumours.
Solution:
“First-in-class” drugs against a new therapeutic target that in combination with standard chemotherapy (cisplatin and docetaxel) will sensitize resistant HNSCC cells and drastically reduce metastasis in HNSCC patients.
Aplication areas:
New therapy for HNSCC and other types of cancer such as pancreatic and breast, among others.
Novelty:
No treatments against the new therapeutic target discovered have been previously reported. These molecules will be first-in-class drugs against this novel target.
Target market:
Big companies and start-ups developing treatments against HNSCC.
TRL: 3
CRL: 2
BRL: 3
IPRL: 5
FRL: 3
More information
if you want to know more about this project do not hesitate to contact us